References

Global epidemiology of nontuberculous mycobacterial pulmonary disease: a review

10.1016/j.ccm.2023.08.012 · 2023 · External reference

Nontuberculous mycobacterial pulmonary disease: patients, principles, and prospects

10.1093/cid/ciae421 · 2024 · External reference

A narrative review of nontuberculous mycobacterial pulmonary disease: microbiology, epidemiology, diagnosis, and management challenges

10.1080/17476348.2023.2283135 · 2023 · External reference

Unresolved reference

2025 · External reference

Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline

10.1093/cid/ciaa241 · 2020 · External reference

Unresolved reference

2024 · External reference

Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis

10.1093/cid/cix517 · 2017 · External reference

Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease

10.1128/aac.01240-16 · 2016 · External reference

Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics

2022 · External reference

Rifampicin has no role in treatment of Mycobacterium avium complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint

10.1183/13993003.02210-2023 · 2024 · External reference

Comprehensive management algorithm for Mycobacterium avium complex pulmonary disease in the real-world setting

10.1513/annalsats.202408-904fr · 2025 · External reference

Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease

10.1164/rccm.201604-0700oc · 2017 · External reference

Simultaneous comparison of multiple treatments: combining direct and indirect evidence

10.1136/bmj.331.7521.897 · 2005 · External reference

Unresolved reference

External reference

Treatment outcomes and safety of clofazimine in nontuberculous mycobacterial pulmonary disease (NTM-PD)

10.1186/s44350-026-00012-1 · 2026 · External reference

Treatment outcomes of Mycobacterium avium complex pulmonary disease with a 2-drug daily regimen using macrolide and ethambutol

10.1093/ofid/ofaf292 · 2025 · External reference

Aminoglycoside susceptibility and treatment outcomes in Mycobacterium avium complex pulmonary disease

10.1016/j.jmii.2025.03.018 · 2025 · External reference

Mycobacterium avium complex disease: current treatment challenges and future directions

2022 · External reference

Unresolved reference

2025 · External reference

Mycobacterium avium complex (MAC) infection in severely immunocompromised people living with HIV: findings from a five-year cohort

10.1177/09564624241297835 · 2025 · External reference

Clinical and immunologic predictors of Mycobacterium avium complex immune reconstitution inflammatory syndrome in a contemporary cohort of patients with human immunodeficiency virus

10.1093/infdis/jiaa669 · 2021 · External reference

Updating the PRISMA reporting guideline for network meta-analysis: a scoping review

10.1016/j.jclinepi.2025.111985 · 2025 · External reference

The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials

10.11124/jbies-22-00430 · 2023 · External reference

The Newcastle–Ottawa Scale for assessing the quality of studies in systematic reviews

2026 · External reference

Comparative efficacy and acceptability of psychosocial interventions for PTSD, depression, and anxiety in asylum seekers, refugees, and other migrant populations: a systematic review and network meta-analysis of randomised controlled studies

2024 · External reference

Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement

10.1183/13993003.00170-2018 · 2018 · External reference

Changes in sputum microbiota during treatment for nontuberculous mycobacterial pulmonary disease

2023 · External reference

Safety and efficacy of nontuberculous mycobacteria treatment among elderly patients

2020 · External reference

Psychological interventions for PTSD, depression, and anxiety in child, adolescent and adult forced migrants: a systematic review and frequentist and Bayesian meta-analyses

10.1002/cpp.3042 · 2024 · External reference

Using selection models to assess sensitivity to publication bias: a tutorial and call for more routine use

2022 · External reference

Clarithromycin Study Group of France. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS

10.1378/chest.107.4.1035 · 1995 · External reference

Canadian HIV Trials Network Protocol 010 Study Group. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin

10.1056/nejm199608083350602 · 1996 · External reference

Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection

10.1097/00002030-199703110-00008 · 1997 · External reference

California Collaborative Treatment Group. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy

10.1086/514116 · 1997 · External reference

ANRS Trial 033 Curavium Group. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium

10.1086/513753 · 1997 · External reference

Veterans Affairs HIV Research Consortium. Randomized, open-label trial of azithromycin plus ethambutol vs clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection

10.1086/514999 · 1998 · External reference

10.1086/520141

10.1086/520141 · 1999 · External reference

Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients

10.1007/s100960050220 · 1999 · External reference

A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex

10.1086/514748 · 1999 · External reference

A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus

10.1086/317468 · 2000 · External reference

10.1086/378807

10.1086/378807 · 2003 · External reference

A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease

10.1016/j.rmed.2006.04.002 · 2007 · External reference

Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease: a preliminary study

10.1513/annalsats.201308-266oc · 2014 · External reference

Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin

10.1378/chest.15-0543 · 2016 · External reference

The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: a nationwide post-marketing study

10.1016/j.jiac.2017.01.007 · 2017 · External reference

Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): a prospective, open-label, randomized study

10.1164/rccm.201807-1318oc · 2018 · External reference

Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study

10.1183/23120541.00466-2021 · 2021 · External reference

Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease: sustainability and durability of culture conversion and safety of long-term exposure

10.1016/j.chest.2021.03.070 · 2021 · External reference

Factors associated with treatment outcome in patients with nontuberculous mycobacterial pulmonary disease: a large population-based retrospective cohort study in Shanghai

10.3390/tropicalmed7020027 · 2022 · External reference

Safety and efficacy of clofazimine as an alternative for rifampicin in Mycobacterium avium complex pulmonary disease treatment: outcomes of a randomized trial

10.1016/j.chest.2023.11.038 · 2024 · External reference

Treatment outcomes of clofazimine-containing regimens in severe Mycobacterium avium complex pulmonary disease

10.1093/ofid/ofad682 · 2024 · External reference

Clofazimine serum concentration and safety/efficacy in nontuberculous mycobacterial pulmonary disease treatment

10.1016/j.rmed.2024.107718 · 2024 · External reference

Analyses on clinical characteristics and related factors of treatment outcomes in patients with nontuberculous mycobacterial pulmonary disease

2024 · External reference

Characteristics of patients with non-tuberculous mycobacterium pulmonary disease and influencing factors of treatment outcomes in Wuxi, Jiangsu

2025 · External reference

Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial

10.1093/annalsats/aaoaf064 · 2026 · External reference

Treatment outcomes of clofazimine-containing regimens in Mycobacterium avium complex pulmonary disease: a retrospective study from two European reference centers

10.1007/s15010-026-02787-x · 2026 · External reference

Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages

10.3389/fmicb.2018.00915 · 2018 · External reference

Effectiveness of amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease in Japanese clinical practice

10.1186/s12890-024-03261-w · 2024 · External reference

Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model

10.1128/aac.01157-23 · 2024 · External reference

Amikacin liposomal inhalation suspension for non-tuberculous Mycobacteria lung infection: a greek observational study

2024 · External reference

Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy

10.1016/j.rmed.2020.106025 · 2020 · External reference

Clinical factors and practical strategies to optimize amikacin liposome inhalation suspension therapy in refractory Mycobacterium avium complex pulmonary disease

10.1186/s12890-026-04413-w · 2026 · External reference

Real-world outcomes of amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease

10.4046/trd.2023.0120 · 2024 · External reference

British HIV Association guidelines on the management of opportunistic infection in people living with HIV: the clinical management of non-tuberculous mycobacteria 2024

10.1111/hiv.13727 · 2024 · External reference

Unresolved reference

External reference

Expert consensus on diagnosis and treatment of non-tuberculous mycobacteria co-infection in patients with HIV/AIDS

2026 · External reference

Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections

10.1183/16000617.0010-2021 · 2021 · External reference

Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease

10.1186/s12890-019-0982-8 · 2019 · External reference

Two-drug versus three-drug regimens for treating Mycobacterium avium complex infection: a systematic review and meta-analysis

10.1016/j.jiph.2025.102711 · 2025 · External reference

Population pharmacokinetic evaluation of amikacin liposome inhalation suspension in patients with treatment-refractory nontuberculous mycobacterial lung disease

10.1007/s13318-020-00669-7 · 2021 · External reference

A systematic review of factors associated with mortality among patients with Mycobacterium avium complex lung disease

10.3390/pathogens12111331 · 2023 · External reference

Mycobacterium avium complex pulmonary disease patients with limited treatment options

10.1183/23120541.00610-2023 · 2024 · External reference

Current and emerging treatment strategies for Mycobacterium avium complex pulmonary disease: a narrative review

10.12771/emj.2025.00080 · 2025 · External reference

Treatment strategies for Mycobacterium avium pulmonary disease

2026 · External reference